PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
The Korean Journal of Internal Medicine10.3904/kjim.2015.0242016312357-366Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cellsDae Sik Kim, Yoo Jin Na, Myoung Hee Kang, Soo-Young Yoon, Chul Won Choihttp://kjim.org/upload/kjim-2015-024.pdf, http://kjim.org/journal/view.php?doi=10.3904/kjim.2015.024, http://www.kjim.org/upload/kjim-2015-024.pdf
Leukemia Research10.1016/s0145-2126(09)70059-1200933S44C021 The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1J. Ohyashiki, S. Okabe, T. Tauchi, K. Ohyashikihttps://api.elsevier.com/content/article/PII:S0145212609700591?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0145212609700591?httpAccept=text/plain
Experimental Hematology10.1016/j.exphem.2017.06.222201753S95Adhesion to stromal cells mediates imatinib resistance in chronic myeloid leukemiaBithiah Grace Jaganathanhttps://api.elsevier.com/content/article/PII:S0301472X17304526?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0301472X17304526?httpAccept=text/plain
Critical Reviews in Oncology/Hematology10.1016/j.critrevonc.2005.06.0072006572145-164Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)Christoph Walz, Martin Sattlerhttps://api.elsevier.com/content/article/PII:S1040842805001459?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1040842805001459?httpAccept=text/plain
Leukemia Research10.1016/s0145-2126(07)70028-0200731S1627 Deferasirox – the novel, once a day oral iron chelatorS.L. Goldberghttps://api.elsevier.com/content/article/PII:S0145212607700280?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0145212607700280?httpAccept=text/plain
Leukemia Research10.1016/j.leukres.2017.11.00720186417-23Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cellsHu Lei, Jin Jin, Meng Liu, Xiangyun Li, Hao Luo, Li Yang, Hanzhang Xu, Yingli Wuhttps://api.elsevier.com/content/article/PII:S0145212617305854?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0145212617305854?httpAccept=text/plain
Value in Health10.1016/j.jval.2015.09.11892015187A460Dasatinib, High-Dose Imatinib And Nilotinib In Chinese Patients With Chronic Phase Of Chronic Myeloid Leukemia With Imatinib-Resistance Or -Intolerance: An Economic EvaluationB Wuhttps://api.elsevier.com/content/article/PII:S1098301515032659?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301515032659?httpAccept=text/plain
Leukemia10.1038/sj.leu.240342620041881321-1331Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistanceA Hochhaus, P La Roséehttp://www.nature.com/articles/2403426.pdf, http://www.nature.com/articles/2403426, http://www.nature.com/articles/2403426.pdf
Cancer Cell10.1016/j.ccr.2011.03.0192011194435-437Unswitch-ABL Drugs Overcome Resistance in Chronic Myeloid LeukemiaLeisl Packer, Richard Maraishttps://api.elsevier.com/content/article/PII:S1535610811001267?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1535610811001267?httpAccept=text/plain
Biomedicine & Pharmacotherapy10.1016/j.biopha.2012.12.0012013673221-227The roles of macromolecules in imatinib resistance of chronic myeloid leukemia cells by Fourier transform infrared spectroscopyYusuf Baran, Cagatay Ceylan, Aylin Camgozhttps://api.elsevier.com/content/article/PII:S0753332212001266?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0753332212001266?httpAccept=text/plain